Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Cost-Effectiveness Analysis of Total Neoadjuvant Therapy Followed by Radical Resection Versus Conventional Therapy for Locally Advanced Rectal Cancer

Wright, Moriah E., M.D.1; Beaty, Jennifer S., M.D.1; Thorson, Alan G., M.D.1; Rojas, Ruben, B.Sc., M.Sc.2; Ternent, Charles A., M.D.1

Diseases of the Colon & Rectum: May 2019 - Volume 62 - Issue 5 - p 568–578
doi: 10.1097/DCR.0000000000001325
Original Contribution: Colorectal Cancer
Buy
SDC
Denotes Associated Video Abstract
Denotes Twitter Account Access

BACKGROUND: Definitive surgery with total mesorectal excision is the mainstay of treatment for locally advanced rectal cancer. Multimodality therapy improves long-term survival. Current standards advise neoadjuvant chemoradiation followed by radical surgery and adjuvant chemotherapy. Nationally, compliance with adjuvant chemotherapy is only 32%. New research evaluates the effectiveness of total neoadjuvant therapy: complete chemotherapy and chemoradiation before surgery.

OBJECTIVE: The aim of this study is to determine the favored treatment for locally advanced rectal cancer by comparing the cost-effectiveness of total neoadjuvant therapy and the current standard of care.

DESIGN: Decision analytical modeling using long-term costs and 5-year disease-free survival was performed to determine the cost-effectiveness after total neoadjuvant therapy and the current standard of care. Sensitivity analysis was used to investigate the effect of uncertainty in model parameters.

SETTINGS: Centers for Medicare & Medicaid Services billing data perspective was adopted and outcomes modeled according to local and national databases and literature consensus.

PATIENTS: Adult patients with stage II or III rectal cancer were selected.

MAIN OUTCOME MEASURES: Cost-effectiveness in disease-free life-years, incremental cost-effectiveness ratio, and net monetary benefit were determined over a 5-year posttreatment period. The favored strategy was determined based on cost-effectiveness and sensitivity analyses.

RESULTS: Cost-effectiveness for total neoadjuvant therapy was 40,708 $/life-year, and, for conventional therapy, cost-effectiveness was 44,248 $/life-year. Sensitivity analysis showed that, for an estimated total neoadjuvant therapy completion rate of 90%, total neoadjuvant therapy would remain the dominant strategy for any adjuvant chemotherapy completion rate of less than 93%.

LIMITATIONS: The samples used to calculate completion rates are small, and survival probabilities are based on existing literature, local database values, and consensus estimates. The model encompasses a 5-year time period from diagnosis.

CONCLUSIONS: Cost-effectiveness analysis shows that a strategy of total neoadjuvant therapy followed by radical surgery is favored over the current standard of care for locally advanced rectal cancer. Sensitivity analysis shows that a low rate of adjuvant chemotherapy administration plays a key role in decreasing the cost-effectiveness of the current standard of care. See Video Abstract at http://links.lww.com/DCR/A942.

1 Section of Colorectal Surgery, Department of Surgery, Creighton University School of Medicine, Omaha, Nebraska

2 Section of Health Economics and Decision Science, School of Health and Related Research, The University of Sheffield, Sheffield, UK

Funding/Support: None reported.

Financial Disclosures: None reported.

Podium presentation at the meeting of the American Society of Colon and Rectal Surgeons, Nashville, TN, May 19 to 23, 2018.

Correspondence: Charles A Ternent, M.D., 9850 Nicholas St, Ste 100, Omaha, NE 68114. E-mail: cat@colonrectalsurgeons.com

© 2019 The American Society of Colon and Rectal Surgeons